{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,10]],"date-time":"2026-06-10T10:42:49Z","timestamp":1781088169161,"version":"3.54.1"},"reference-count":34,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,5,19]],"date-time":"2022-05-19T00:00:00Z","timestamp":1652918400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Genet."],"abstract":"<jats:p>Omeprazole is extensively used to manage gastroesophageal reflux disease (GERD). It is primarily metabolized by CYP2C19. The <jats:italic>CYP2C19*17<\/jats:italic> (rs12248560) allele and the recently described <jats:italic>CYP2C:TG<\/jats:italic> haplotype (rs11188059 and rs2860840) are associated with increased enzymatic activity, and may reduce omeprazole exposure. This observational study aimed to investigate the association between these genetic variants and omeprazole treatment failure in GERD. We recruited predominantly New Zealand European GERD patients who either did not respond to omeprazole or experienced breakthrough heartburn symptoms despite at least 8\u00a0weeks of omeprazole (\u226540\u00a0mg\/day). The GerdQ score was used to gauge symptomatic severity. A total of 55 cases were recruited with a median age (range) of 56\u00a0years (19\u201382) and GerdQ score of 11 (5\u201317). Of these, 19 (34.5%) were <jats:italic>CYP2C19*17<\/jats:italic> heterozygotes and two (3.6%) were <jats:italic>CYP2C19*17<\/jats:italic> homozygotes. A total of 30 (27.3%) <jats:italic>CYP2C:TG<\/jats:italic> haplotypes was identified in our cohort, with seven (12.7%) <jats:italic>CYP2C:TG<\/jats:italic> homozygotes, and 16 (29%) <jats:italic>CYP2C:TG<\/jats:italic> heterozygotes. No significant differences were observed for overall <jats:italic>CYP2C19*17<\/jats:italic> alleles, <jats:italic>CYP2C19*17\/*17<\/jats:italic>, overall <jats:italic>CYP2C:TG<\/jats:italic> haplotypes, and <jats:italic>CYP2C:TG<\/jats:italic> heterozygotes (<jats:italic>p<\/jats:italic> &amp;gt; 0.05 for all comparisons). Gastroscopy and 24-h esophageal pH\/impedance tests demonstrated objective evidence of GERD in a subgroup of 39 (71%) cases, in which the <jats:italic>CYP2C:TG\/TG<\/jats:italic> was significantly enriched (<jats:italic>p<\/jats:italic> = 0.03) when compared with the haplotype frequencies in a predominantly (91%) New Zealand European reference population, but not the <jats:italic>CYP2C19*17\/*17<\/jats:italic> (<jats:italic>p<\/jats:italic> &amp;gt; 0.99), when compared with the allele frequencies for the non-Finnish European subset of gnomAD. We conclude that omeprazole treatment failure in GERD is associated with <jats:italic>CYP2C:TG\/TG<\/jats:italic>, but not <jats:italic>CYP2C19*17<\/jats:italic>.<\/jats:p>","DOI":"10.3389\/fgene.2022.869160","type":"journal-article","created":{"date-parts":[[2022,5,19]],"date-time":"2022-05-19T05:00:06Z","timestamp":1652936406000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":18,"title":["Omeprazole Treatment Failure in Gastroesophageal Reflux Disease and Genetic Variation at the CYP2C Locus"],"prefix":"10.3389","volume":"13","author":[{"given":"Ping Siu","family":"Kee","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simran D. S.","family":"Maggo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin A.","family":"Kennedy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Murray L.","family":"Barclay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Allison L.","family":"Miller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Klaus","family":"Lehnert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maurice A.","family":"Curtis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard L. M.","family":"Faull","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Remai","family":"Parker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul K. L.","family":"Chin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2022,5,19]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"e12574","DOI":"10.1111\/hel.12574","article-title":"Personalized Therapy for Helicobacter pylori : CYP2C19 Genotype Effect on First\u2010line Triple Therapy","volume":"24","author":"Ar\u00e9valo Galvis","year":"2019","journal-title":"Helicobacter"},{"key":"B2","doi-asserted-by":"publisher","first-page":"1368","DOI":"10.1053\/j.gastro.2016.02.012","article-title":"Esophageal Disorders","volume":"150","author":"Aziz","year":"2016","journal-title":"Gastroenterology"},{"key":"B3","doi-asserted-by":"publisher","first-page":"767","DOI":"10.1111\/j.1365-2125.2008.03104.x","article-title":"Increased Omeprazole Metabolism in Carriers of the CYP2C19*17 Allele; a Pharmacokinetic Study in Healthy Volunteers","volume":"65","author":"Baldwin","year":"2008","journal-title":"Br. J. Clin. Pharmacol."},{"key":"B4","doi-asserted-by":"publisher","first-page":"786","DOI":"10.1002\/cpt.2233","article-title":"A Novel CYP2C\u2010Haplotype Associated with Ultrarapid Metabolism of Escitalopram","volume":"110","author":"Br\u00e5ten","year":"2021","journal-title":"Clin Pharma Ther."},{"key":"B5","doi-asserted-by":"publisher","first-page":"588","DOI":"10.1111\/1751-2980.12393","article-title":"Effects of Different Omeprazole Dosing on Gastric pH in Non-variceal Upper Gastrointestinal Bleeding: A Randomized Prospective Study","volume":"17","author":"Chwiesko","year":"2016","journal-title":"J. Dig. Dis."},{"key":"B6","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1038\/tpj.2010.39","article-title":"Association between CYP2C19*17 and Metabolism of Amitriptyline, Citalopram and Clomipramine in Dutch Hospitalized Patients","volume":"11","author":"de Vos","year":"2011","journal-title":"Pharmacogenomics J."},{"key":"B7","article-title":"DNA Collection Kits for Research: Collect Superior Samples for Your Genetic Analysis","year":"2021"},{"key":"B8","doi-asserted-by":"publisher","first-page":"720","DOI":"10.1111\/j.1365-2036.2010.04406.x","article-title":"Systematic Review: Persistent Reflux Symptoms on Proton Pump Inhibitor Therapy in Primary Care and Community Studies","volume":"32","author":"El-Serag","year":"2010","journal-title":"Aliment. Pharmacol. Ther."},{"key":"B9","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1007\/s00431-017-3051-4","article-title":"Association between CYP2C19 Extensive Metabolizer Phenotype and Childhood Anti-reflux Surgery Following Failed Proton Pump Inhibitor Medication Treatment","volume":"177","author":"Franciosi","year":"","journal-title":"Eur. J. Pediatr."},{"key":"B10","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1002\/jcph.977","article-title":"Association BetweenCYP2C19*17Alleles and pH Probe Testing Outcomes in Children with Symptomatic Gastroesophageal Reflux","volume":"58","author":"Franciosi","year":"","journal-title":"J. Clin. Pharmacol."},{"key":"B11","doi-asserted-by":"publisher","first-page":"552","DOI":"10.1016\/s0009-9236(99)70075-5","article-title":"Genotype Status and Effect of Omeprazole on Intragastric pH in Humans","volume":"65","author":"Furuta","year":"1999","journal-title":"Clin. Pharmacol. Ther."},{"key":"B12","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1002\/cpt.597","article-title":"Clinical Pharmacogenetics Implementation Consortium Guideline (CPIC) for CYP2D6 and CYP2C19 Genotypes and Dosing of Tricyclic Antidepressants: 2016 Update","volume":"102","author":"Hicks","year":"2017","journal-title":"Clin. Pharmacol. Ther."},{"key":"B13","doi-asserted-by":"publisher","first-page":"1030","DOI":"10.1111\/j.1365-2036.2009.04142.x","article-title":"Development of the GerdQ, a Tool for the Diagnosis and Management of Gastro-Oesophageal Reflux Disease in Primary Care","volume":"30","author":"Jones","year":"2009","journal-title":"Aliment. Pharmacol. Ther."},{"key":"B14","doi-asserted-by":"publisher","first-page":"434","DOI":"10.1038\/nmeth.373910.1038\/s41586-020-2308-7","article-title":"The Mutational Constraint Spectrum Quantified from Variation in 141,456 Humans","volume":"581","author":"Karczewski","year":"2020","journal-title":"Nature"},{"key":"B15","doi-asserted-by":"publisher","first-page":"069","DOI":"10.5056\/jnm14078","article-title":"Predictive Factors of Response to Proton Pump Inhibitors in Korean Patients with Gastroesophageal Reflux Disease","volume":"21","author":"Kim","year":"2015","journal-title":"J. Neurogastroenterol. Motil."},{"key":"B16","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1378\/chest.121.2.625","article-title":"Oral Corticosteroids Increase Esophageal Acid Contact Times in Patients with Stable Asthma","volume":"121","author":"Lazenby","year":"2002","journal-title":"Chest"},{"key":"B17","doi-asserted-by":"publisher","first-page":"1417","DOI":"10.1002\/cpt.2015","article-title":"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2C19 and Proton Pump Inhibitor Dosing","volume":"109","author":"Lima","year":"2021","journal-title":"Clin. Pharmacol. Ther."},{"key":"B18","doi-asserted-by":"publisher","first-page":"1199","DOI":"10.3389\/fgene.2019.01199","article-title":"Common CYP2D6, CYP2C9, and CYP2C19 Gene Variants, Health Anxiety, and Neuroticism Are Not Associated with Self-Reported Antidepressant Side Effects","volume":"10","author":"Maggo","year":"2019","journal-title":"Front. Genet."},{"key":"B19","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1002\/humu.20892","article-title":"A New Zealand Platform to Enable Genetic Investigation of Adverse Drug Reactions","volume":"130","author":"Maggo","year":"2017","journal-title":"N. Z. Med. J."},{"key":"B20","first-page":"646","article-title":"The Spectrum of Reflux Phenotypes","volume":"15","author":"Mahoney","year":"2019","journal-title":"Gastroenterol. Hepatol. (N Y)"},{"key":"B21","article-title":"Fisher Exact Probability Calculator","year":"2021"},{"key":"B22","first-page":"203","article-title":"Interaction of Proton Pump Inhibitors with Cytochromes P450: Consequences for Drug Interactions","volume":"69","author":"Meyer","year":"1996","journal-title":"Yale J. Biol. Med."},{"key":"B23","doi-asserted-by":"publisher","first-page":"1215","DOI":"10.1093\/nar\/16.3.1215","article-title":"A Simple Salting Out Procedure for Extracting DNA from Human Nucleated Cells","volume":"16","author":"Miller","year":"1988","journal-title":"Nucl. Acids Res."},{"key":"B24","article-title":"New Zealand Peoples","year":"2008"},{"key":"B25","doi-asserted-by":"publisher","first-page":"1567","DOI":"10.1038\/ajg.2015.314","article-title":"Long-Term Loss of Response in Proton Pump Inhibitor-Responsive Esophageal Eosinophilia Is Uncommon and Influenced by CYP2C19 Genotype and Rhinoconjunctivitis","volume":"110","author":"Molina-Infante","year":"2015","journal-title":"Am. J. Gastroenterol."},{"key":"B26","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1111\/j.1365-2362.2005.01543.x","article-title":"Developments in the Inhibition of Gastric Acid Secretion","volume":"35","author":"Mossner","year":"2005","journal-title":"Eur. J. Clin. Invest."},{"key":"B27","doi-asserted-by":"publisher","first-page":"S38","DOI":"10.5152\/tjg.2017.11","article-title":"Which Drugs Are Risk Factors for the Development of Gastroesophageal Reflux Disease?","volume":"28","author":"Mungan","year":"2017","journal-title":"Turk J. Gastroenterol."},{"key":"B28","doi-asserted-by":"publisher","first-page":"5814","DOI":"10.1038\/s41598-020-62795-1","article-title":"Global Prevalence and Risk Factors of Gastro-Oesophageal Reflux Disease (GORD): Systematic Review with Meta-Analysis","volume":"10","author":"Nirwan","year":"2020","journal-title":"Sci. Rep."},{"key":"B29","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1515\/dmdi-2012-0038","article-title":"Regulatory Polymorphisms in CYP2C19 Affecting Hepatic Expression","volume":"28","author":"Sanford","year":"2013","journal-title":"Drug Metabol. Drug Interact."},{"key":"B30","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1016\/j.clpt.2005.10.002","article-title":"A Common Novel CYP2C19 Gene Variant Causes Ultrarapid Drug Metabolism Relevant for the Drug Response to Proton Pump Inhibitors and Antidepressants","volume":"79","author":"Sim","year":"2006","journal-title":"Clin. Pharmacol. Ther."},{"key":"B31","doi-asserted-by":"publisher","first-page":"27","DOI":"10.5009\/gnl15502","article-title":"25 Years of Proton Pump Inhibitors: A Comprehensive Review","volume":"11","author":"Strand","year":"2017","journal-title":"Gut Liver"},{"key":"B32","article-title":"Anticholinergic Activity of Medications","year":"2021"},{"key":"B33","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1002\/cpt.2350","article-title":"An Evidence\u2010Based Framework for Evaluating Pharmacogenomics Knowledge for Personalized Medicine","volume":"110","author":"Whirl\u2010Carrillo","year":"2021","journal-title":"Clin Pharma Ther."},{"key":"B34","doi-asserted-by":"publisher","first-page":"e14075","DOI":"10.1111\/nmo.14075","article-title":"ESNM\/ANMS Consensus Paper: Diagnosis and Management of Refractory Gastro\u2010esophageal Reflux Disease","volume":"33","author":"Zerbib","year":"2021","journal-title":"Neurogastroenterol. Motil."}],"container-title":["Frontiers in Genetics"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fgene.2022.869160\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,5,19]],"date-time":"2022-05-19T05:00:10Z","timestamp":1652936410000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fgene.2022.869160\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,5,19]]},"references-count":34,"alternative-id":["10.3389\/fgene.2022.869160"],"URL":"https:\/\/doi.org\/10.3389\/fgene.2022.869160","relation":{},"ISSN":["1664-8021"],"issn-type":[{"value":"1664-8021","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,5,19]]},"article-number":"869160"}}